At TheraSonic, we aim at transforming the treatment of brain diseases by enabling drug delivery to the brain.
The blood-brain barrier (BBB) acts as a critical defense mechanism against harmful substances. However, this selectivity also impedes the delivery of therapeutic agents to the brain, a significant challenge in treating neurological disorders.
TheraSonic non-invasive device transiently disrupts the BBB using low-intensity focused ultrasound which facilitates the delivery of therapeutics at targeted locations in the brain.
Backed by over 15 years of academic research, this innovative technology enables non-invasive delivery of therapeutics to targeted areas of the brain.
Our real-time dosimetry solution ensures safe disruption of the blood-brain barrier using focused ultrasound for repeated treatments.
Based on state-of-the art neuro-navigation solution, our system ensures precise targeting in the brain.
Leveraging our medical robot technology, our platform enables treatment of multiple targets and large volume in a single session.
Meet the talented individuals behind our groundbreaking medical device that aims to enhance drug delivery to the brain.
Benoit Larrat, PhD.
Founder, CEO
Anthony Novell, PhD.
Founder, CSO
Joseph André, PhD.
COO
Fabienne Betting
CTO
From the origin, TheraSonic has grown amongst leaders and innovators in their respective field. TheraSonic is proud to includes CEA investissement, Healthtech venture studio M2care, as well as Gustave Roussy Transfert as their first investors and partners.
TheraSonic is an innovative company in the field of medical devices. We are currently looking for a Validation and Verification Manager to join our dynamic team and contribute to the development of our therapeutic agent delivery device for…
We are looking for an experiencedmechanical engineer to join our innovative product development team.…
We are thrilled to announce that TheraSonic will be participating in the Annual International…
TheraSonic will be present at the Robotique Médicale Made In France conference on October…